Minimal Residual Disease Testing Market Size & Share 2023 to 2032
Market Size by Technology (Flow-cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS)), by Application (Lymphoma, Leukemia, Solid Tumors), by End Use, & Forecast.
Report ID: GMI5870
|
Published Date: May 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Minimal Residual Disease Testing Market Size
Minimal Residual Disease Testing Market size was valued at around USD 2.45 billion in 2022 and is estimated to reach over USD 4.1 billion by 2032.
Minimal Residual Disease Testing Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Advancements in minimal residual disease testing technologies result in an improvement in cancer treatment procedures. Additionally, these minimal residual disease tests are specially designed to measure the effectiveness of treatment, help doctors confirm & monitor remissions, and possibly identify an early return of cancer. As per the Leukemia & Lymphoma Society, the most widely used tests to evaluate minimal residual disease are flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) among others.
The minimal residual disease testing market from digital technology is also providing application prospects for personalized minimal residual disease diagnosis through quantifying nucleic acids precisely. These advantages pertaining to minimal residual disease testing are attributable to ongoing R&D activities and significant technological advancements. As a result, the recent technological advancements are set to increase the demand for minimal residual disease testing. Minimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment.
However, the stringent regulatory framework related to minimal residual disease testing may hamper the market growth. The U.S. FDA has rigid regulatory compliances and complex approval procedures that may obstruct the market gains. The majority of minimal residual tests need a premarket notification, or 510(k) process prior to their commercialization in the market. Such stringent product regulations may lead to penalties and loss of market access in a global marketplace.
COVID-19 Impact
The recent outbreak of COVID-19 had negatively impacted the minimal residual disease testing market revenue. The lucrative demand for COVID-19 testing had substantially impacted other disease testing services. During the initial period, the incidence, as well as the mortality rate of COVID-19, was highest, and people tended to avoid any other treatment or diagnosis procedures at facilities. The risk of infection during cancer diagnostic test at point-of-care facilities had resulted in procedure deferral.
In addition, the high rate of COVID-19 incidence across the globe had driven the need for expansion of existing testing facilities. These factors had shifted focus on increasing COVID-19 testing-related services leading to the decline in the point-of-care testing of other diseases including cancer testing, thus impeding the related product sales during the period. However, the cancer patients were at a higher risk of COVID-19 infection-related complications. A considerable portion of cancer patients was diagnosed with severe COVID-19 that had continued the need for disease testing to a certain limit.
Minimal Residual Disease Testing Market Trends
The increasing prevalence of cancer is anticipated to proliferate market growth in the coming years. The growing geriatric population suffering from cancer has accelerated the progress for diagnostic procedures that has further propelled the market expansion positively. Cancer including blood cancer, lymphoma, and solid tumors among others promote substantial disease burden. These ailments inflict health care costs and affect the health-associated quality of life.
According to the Leukemia and Lymphoma Society, in 2022, around 1.24 million blood cancer cases occurred across the globe that include a variety of chronic medical conditions. In addition, solid tumors represent around 90% of adult human cancers that leads to a large number of patients opting for minimal residual disease testing for diagnosis.
Furthermore, several government organizations across the globe have implemented strict regulations and recommendations to continuously monitor the treatment efficacy of patients suffering from cancer. Likewise, hospitals and clinics have focused more on continuous testing during treatment procedures. The surge in the prevalence & morbidity associated with cancer is amongst the key variables that are set to prove beneficial for the market.
Minimal residual disease testing market players and governments are collaboratively emphasizing on providing highly sensitive & specific diagnosis during treatment procedures that have resulted in aligning the minimal residual disease testing as an essential tool in healthcare facilities. As a result, the rise in in-patient hospitalization for various diagnosis and treatments is projected to fuel the minimal residual disease testing adoption.
Minimal Residual Disease Testing Market Analysis
Based on technology, the minimal residual disease testing market is segmented as flow-cytometry, polymerase chain reaction (PCR), next generation sequencing (NGS), and others. The polymerase chain reaction (PCR) held the considerable market share in 2022 and was valued at over USD 606 million. The significant segment progression is primarily attributed to novel technological advancement and an increase in the awareness of benefits related to the use of digital PCR (dPCR). This highly sensitive digital polymerase chain reaction allows absolute quantification through accurate molecular detection.
In the coming years, the popularity of minimal residual disease PCR test will produce even greater amounts of data in real-time through the integration of big data and artificial intelligence that will effectively reduce the mortality associated with cancer. Thus, the novel advancements, the emergence of integrative technologies that promote precision & reduce turn-around time, and associated benefits are projected to accelerate the market evolution.
Based on application, the minimal residual disease testing market is segmented as lymphoma, leukemia, solid tumors, and others. The lymphoma segment held a dominant market share in 2022 and was valued at around USD 891 million. The increasing prevalence of lymphoma is anticipated to drive the market in the forecast years. As per the American Cancer Society, in 2021, around 90,300 people were diagnosed with lymphoma in the U.S. This disease burden is expected to reach higher with each passing year. The common symptoms of having lymphoma include swelling of lymph nodes in neck, in armpits or groin.
Moreover, immune system disorders comprising HIV/AIDS, autoimmune disorders comprising rheumatoid arthritis, and other factors are significantly contributing to the surging incidence of blood cancer disorders. The next-generation minimal residual disease testing model will be highly sensitive & specific, incorporating novel technologies to show how well the patient has responded to treatment.
Based on end-use, the minimal residual disease testing market is segmented as hospitals, specialty clinics, diagnostic centers, and others. The hospitals segment is projected to reach more than USD 1.9 billion by 2032. This high market share is owing to the rising prevalence of cancer requiring minimal residual disease testing, soaring use of novel cancer tests in hospital settings, and the subsequent number of hospital admissions among others. The availability of a broad spectrum of kits for performing these tests with proven accuracy is set to drive product preference in hospitals. Growing admissions with cancer ailments and growing disease screening initiatives along with the accessibility to board-certified healthcare professionals are some other variables that are augmenting the segment enlargement positively.
Also, the rising disease burden in developed economies with enhanced healthcare infrastructure is projected to stimulate the diagnosis & treatment rate at hospitals. As a result, accessibility to an effective diagnosis coupled with the rising prevalence of cancer diseases and associated conditions will boost the patient visits to hospitals.
North America minimal residual disease testing market is anticipated to expand at a considerable pace to reach around USD 1.8 billion by 2032. The growing prevalence of cancer and the growing adoption of advanced cancer diagnostic test are some of the major factors that are driving the market growth in the country. For instance, as per the American Cancer Society, in 2022, around 1,918,030 new cancer cases and 609,360 cancer deaths were reported in the U.S.
Moreover, the rising patient influx associated with several chronic blood cancer disorders including leukemia, lymphoma, and myeloma among others is leading to increased product demand across several states in the U.S. According to the American Cancer Society, in 2021, 61,000 leukemia cases were reported in the U.S. As a result, minimal residual disease testing is widely adopted for residual disease & recurrence monitoring in patients with early-stage cancer by hospitals & specialty clinics in the country.
Minimal Residual Disease Testing Market Share
Some of the major minimal residual disease testing market players operating in the minimal residual disease testing industry are
Minimal Residual Disease Testing Industry News:
Minimal residual disease testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD (million) and volume (Units) from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
By Technology, 2018 - 2032 (USD Million & Units)
By Application, 2018 - 2032 (USD Million)
By End-use, 2018 - 2032 (USD Million)
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →